Tom Wiggans, Pardes Biosciences CEO

Biotech launched dur­ing Covid — for Covid — looks for strate­gic al­ter­na­tives af­ter an­tivi­ral fails PhII tri­al

A next-gen Covid-19 an­tivi­ral has flunked a Phase II test, forc­ing its de­vel­op­er to go in­to some se­ri­ous soul search­ing.

The mid-stage read­out was cru­cial …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.